Qrons Appoints Dr. Motti Ratmansky as Special Advisor for IND & Clinical Trial Preparations

New York, NY, May 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. QRON, an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), both concussions and penetrating injuries, announced today the appointment of Dr. Motti Ratmansky, a member of Qrons' Scientific Advisory Board as Special Advisor to the Company for IND & Clinical Trials.  Remaining on the Scientific Advisory Board, Dr. Ratmansky will take a more active role as Senior Advisor to assist the Company in preparing for its IND ("Investigational New Drug") filing. This represents the Company's further steps to enhance its operation for its IND and clinical trial enabling process, including the possible addition of US-based individuals.

Jonah Meer, Qrons Chief Executive Officer, commented, "Dr. Ratmansky is a highly experienced, well esteemed doctor. We have benefited from his guidance during his time on our Advisory Board. As we have been developing our QS100™ and QS 200™ product candidates there is now a need for the focus of a highly qualified person to advise us as we begin to prepare for dealing with the FDA IND program and clinical trials. Dr. Ratmansky is that person!"

Dr. Ratmansky is a qualified good clinical practice researcher and a member of Loewenstein's Hospital Institutional Review Board (IRB), with vast experience in human clinical studies design, regulatory approval and ethical aspects. He is also a member of the hospital's research funding committee, evaluating the financial aspects of clinical trials design. Loewenstein Hospital is the largest and leading Israeli hospital in the field of rehabilitation medicine.

As a clinical trial lead investigator, he is responsible for preparing applications to the local IRB and U.S. National Institute of Health (NIH) National Library of Medicine registration, outlining the proposed clinical study and patients consent forms. He is currently serving as a lead investigator in 12 clinical trials.

As a medical consultant in recent years to early stage biotech companies, he maintains the linkage between the R&D and the regulatory strategy by interacting with FDA regulatory consultants' designing research plans in accordance with regulatory demands. He has published several original research papers and reviews in international peer reviewed medical journals.

Dr. Ratmansky holds an M.D. degree from the Technion Institute and B. Med.Sc from The Hebrew University as well as two specialties both in pain and rehabilitation medicine with 20 years of experience in clinical medicine. 

Ido Merfeld, Qrons co-Founder and Head of Product, stated, "I have had the privilege of working with Dr. Ratmansky on our Scientific Advisory Board. We are thrilled that he sees the promise of our products and has agreed to provide special assistance and focus as we begin preparing for an IND and clinical trials."

Dr. Ratmansky: "I've had the pleasure of working with Ido and the Qrons team as a member of the Scientific Advisory Board for the last year and a half and have seen first-hand the revolutionary treatment they are developing for TBI. I am excited to provide special assistance to shepherd the product candidates to an IND filing and clinical trials."

About Qrons Inc.

Headquartered in New York City, the Company is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussion. The Company has two candidate products for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material QS100™ an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™ an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement ("License Agreement") and related service agreements with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team at the Chemistry Department, aiming to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating, a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

Contact:

Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080